D. Rauch

Type de document

Articles (3)

Co-auteur

Date

Source

Mot-clé

toxicité (3) thérapie (3) procès (3) taux (3) Treatment (3) Methods (3) Therapeutics (3) Patients (3) Cancer (3) Methods (3) Toxicology (3) Patients (3) sécurité (2) qualité de vie (2) maladie (2) point (2) cancer (2) survie (2) Chemotherapy (2) Cancer (2) Theater (2) Survival (2) Quality of life (2) Drama (2) Days (2) Cycles (2) Chemotherapy (2) Breast (2) Acting (2) Bevacizumab (2)

Documents écrit par D. Rauch (3) | parle de D. Rauch (0)

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
C. Rochlitz et al. (2016)
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06).
C. Rochlitz et al. (2011)
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.
D'Addario G. et al. (2008)